Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug - STAT
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug STAT
Eli Lilly Company News
Eli Lilly and Company (LLY) Grew Revenue 48% as GLP-1 Demand Accelerated: Can Growth Continue? - Yahoo Finance Singapore
Eli Lilly and Company (LLY) Grew Revenue 48% as GLP-1 Demand Accelerated: Can Growth Continue? Yahoo Finance Singapore
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? - The Motley Fool
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? The Motley Fool
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies - STAT
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies STAT
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer - TradingView
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer TradingView
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide. - The Motley Fool
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide. The Motley Fool
Eli Lilly Hit With Retaliation Suit Concerning Mounjaro Sales - Bloomberg Law News
Eli Lilly Hit With Retaliation Suit Concerning Mounjaro Sales Bloomberg Law News
Eli Lilly releases Foundayo sleep apnea data - Seeking Alpha
Eli Lilly releases Foundayo sleep apnea data Seeking Alpha
Eli Lilly plans to file US application for Foundayo to treat apnea — CNBC - UA.NEWS
Eli Lilly plans to file US application for Foundayo to treat apnea — CNBC UA.NEWS
Eli Lilly takes aim at illicit market for its experimental weight-loss drug - CBS News
Eli Lilly takes aim at illicit market for its experimental weight-loss drug CBS News
Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising - NBC News
Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising NBC News
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - Reuters
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients - Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters
Breakingviews - COMMENTARY: Eli Lilly is pharma’s latest victim of success - Reuters
Breakingviews - COMMENTARY: Eli Lilly is pharma’s latest victim of success Reuters
Eli Lilly stock gains as Foundayo data broaden obesity case - ad-hoc-news.de
Eli Lilly stock gains as Foundayo data broaden obesity case ad-hoc-news.de
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes - Eli Lilly
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes Eli Lilly
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 - Eli Lilly
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 Eli Lilly
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas - CNBC
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas CNBC
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - Eli Lilly
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market Eli Lilly
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly
Lilly announces three acquisitions to build infectious disease portfolio - Eli Lilly
Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - Eli Lilly
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility Eli Lilly
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - Eli Lilly
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Eli Lilly
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - Eli Lilly
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility Eli Lilly
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - Eli Lilly
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines Eli Lilly
Lilly to acquire Orna Therapeutics to advance cell therapies - Eli Lilly
Lilly to acquire Orna Therapeutics to advance cell therapies Eli Lilly
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance - Eli Lilly
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance Eli Lilly
Eli Lilly becomes first drugmaker to hit $1 trillion in market value - BioPharma Dive
Eli Lilly becomes first drugmaker to hit $1 trillion in market value BioPharma Dive
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet - Eli Lilly
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet Eli Lilly
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI - Eli Lilly
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI Eli Lilly
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - Eli Lilly
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia Eli Lilly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial - Eli Lilly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Eli Lilly
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - Eli Lilly
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans Eli Lilly
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - Eli Lilly
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance Eli Lilly
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas - Eli Lilly
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas Eli Lilly
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity - Eli Lilly
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Eli Lilly